BioNTech Investor Day Presentation Deck

mRNA technology I saRNA could induce higher and extended in vitro and in vivo expression compared to mRNA in vitro expression Increased expression mock Internal data. mRNA (C2C12 cells, equim olar RNA transfer) saRNA in vivo expression Total Flux [p/s] 1.5x107. 1.0x107- 5.0x106. 3x105. 2x106- 1x106- 0 6h Cap Backbone-optimized nucleoside-modified RNA (modRNA) W UTR W ψ ψψ Antigen UTR A30-L-A70 D 111 D 1 2 3 6 10 13 time after i.m. application [days] Multi-platform engine *Self-amp RNA mRNA saRNA showed potential as a vaccine modality with much lower doses Comparable immunogenicity with approximately 100-fold lower doses of saRNA compared to mRNA BIONTECH 31

View entire presentation